CFP
HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
QUICK SEARCH:   [advanced]


     

Can Fam Physician
Vol. 55, No. 3, March 2009, pp.257 - 259
Copyright © 2009 by The College of Family Physicians of Canada
This Article
Right arrow Abstract Freely available
Right arrow Résumé
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rogovik, A. L.
Right arrow Articles by Goldman, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogovik, A. L.
Right arrow Articles by Goldman, R. D.

Child Health Update

Should weight-loss supplements be used for pediatric obesity?

Alex L. Rogovik, MD PhD and Ran D. Goldman, MD
Correspondence: Dr Ran D. Goldman, BC Children’s Hospital, Department of Pediatrics, Room K4-226, Ambulatory Care Building, 4480 Oak St, Vancouver, BC V6H 3V4; telephone 604 875-2345, extension 5217; fax 604 875-2414; e-mailrgoldman{at}cw.bc.ca

Childhood obesity is one of the most important public health concerns. According to recent estimates from the 2004 Canadian Community Health Survey, 26% of Canadian children and adolescents aged 2 to 17 years are overweight or obese, compared with 15% in 1979,1 and now it is the most common childhood disorder.

Options available for treatment of obesity in children include behavioural and dietary modifications, pharmacotherapy, and weight-loss supplements. Recommended behavioural and dietary modifications include promoting physical activity, limiting "screen time" (ie, watching television or playing video or computer games) to no more than 2 hours a day, and limiting consumption of energy-dense snack foods high in sugar and fat.2 These methods, however, remain largely ineffective because family-oriented behavioural and dietary programs require a great deal of time and effort from the parents, which is not always possible for working families.

Weight-loss supplements

No studies have examined the use of weight-loss supplements other than fibre supplements in children and adolescents. In the United States, however, 11% of adolescents aged 14 to 19 years have used weight-loss supplements in their lifetimes,3 which is comparable to adult use. Sales of weight-loss supplements, the fastest growing segment of the dietary supplement industry, increase at a rate of 10% to 20% per year.4 Supplements are viewed by patients as being natural and are assumed to be safer than prescription drugs. In addition, they represent alternatives to failed attempts at weight loss with the use of more conventional approaches.

Most weight-loss supplements include multiple components, often more than 10. Common ingredients of weight-loss supplements categorized by mechanism of action are presented in Table 1.4


View this table:
[in this window]
[in a new window]

  		Table 1 Common ingredients of weight-loss supplements, categorized by mechanism of action

 
The majority of weight-loss supplements have not been clearly demonstrated to be either effective or safe, even in adults, and many have been associated with serious adverse events.5 In addition, the multiple components in weight-loss supplements create possibility of interactions, either among ingredients or with concurrently taken medications. Furthermore, many components, such as herbal extracts, contain multiple potentially active ingredients. Even if individual components of a weight-loss product are demonstrated to be safe, the combination of them might not be.6 Many supplements have been found to be contaminated with harmful ingredients7 or mislabeled regarding actual ingredients of the supplement.

Weight-loss supplements are widely advertised and disseminated over the Internet, although many of them have little or no data to support claims and some, such as dinitrophenol, are life-threatening.8 Very few supplements demonstrate clinical efficacy, with no evidence beyond reasonable doubt that any specific dietary supplement is effective for long-term reduction of body weight. Short-term efficacy for adults was demonstrated for ephedra and ephedrine-containing products9; however, since April 2004, their sale has been prohibited in the United States because of concerns about serious adverse events and increased risk of psychiatric, autonomic, or gastrointestinal symptoms and heart palpitations.5 Citrus aurantium—an herb that contains synephrine, a sympathetic {alpha}-adrenergic agonist similar to ephedrine—is now commonly used as a substitute for ephedra in weight-loss supplements.10 Bitter orange, however, demonstrated no statistically significant benefit for weight loss (P > .05)10 and, in addition to the adverse effects reported with ephedrine, it can also cause photosensitivity and interact with certain drugs, increasing their concentration.4

There is some evidence of benefit for chromium picolinate, chitosan, conjugated linoleic acid (CLA), hydroxycitric acid, pyruvate, and fibre supplements in adults. Although chromium picolinate appears to have a small weight-reduction effect,11 several cases of rhabdomyolysis or renal failure in patients taking chromium were reported, raising doubts about its safety. There is some evidence that chitosan is more effective than placebo in the short-term treatment of obesity, but results obtained from high-quality trials indicate that the effect of chitosan on body weight is minimal and unlikely to be of clinical significance.12 Conjugated linoleic acid appears to attenuate increases in body weight and body fat in several animal models; however, results from 13 clinical trials in humans found little evidence to show that CLA reduces body weight and suggested that it might have adverse effects on human health via redistribution of fat deposition.13 Several studies performed using Garcinia cambogia in overweight and obese adult subjects are inconsistent and yield conflicting results.14 Although pyruvate has been reported to reduce body fat mass and body fat percentage,15 the evidence is weak.

No studies of weight-loss supplements, other than fibre supplements, in children have been conducted. Intake of dietary fibre is inversely associated with body weight, body fat, and body mass index.16 Its mechanisms for weight reduction include promoting satiation, decreasing absorption of macronutrients, and altering secretion of gut hormones. The average fibre intake in North America is less than half of recommended levels. Although increasing consumption of fibre (eg, fruits, vegetables, whole grains, legumes) with diet is an important step to curb the obesity epidemic, the addition of fibre supplements should also be considered. Glucomannan, a soluble and highly viscous dietary fibre derived from the root of the konjac plant, can promote weight loss in overweight and obese individuals and improve lipid and lipoprotein parameters and glycemic status17 with minimal gastrointestinal side effects. Although little data exist on psyllium for weight reduction, it has been shown to improve glucose homeostasis and the lipid and lipoprotein profile in obese children.18 Inulin (from chicory root) is being sold in many mainstream stores as a fibre supplement, including for use in children; however, its weight-lowering effect has not been studied.

Pharmacotherapy

Pharmacotherapy should be considered for extremely obese children (body mass index ≥ 2 units above the 95th percentile) older than 12 years of age who are resistant to 12-month dietary and lifestyle modifications19; those with marked abdominal adiposity, impaired glucose tolerance or insulin resistance, steatohepatitis, and ovarian hyperandrogenism; and those with strong family history of diabetes, myocardial infarction, or stroke. Orlistat, a fat absorption inhibitor, is the only prescription drug indicated by the Food and Drug Administration for the treatment of overweight adolescents.2 It can cause transient gastrointestinal adverse effects, such as abdominal discomfort, flatulence, and diarrhea, due to unabsorbed fat excreted in the feces.19 However, side effects of orlistat can be prevented by concomitant prescription of dietary fibres.20

Conclusion

Weight-loss supplements lack sufficient data supporting their efficacy and safety, even in adults. Most weight-loss supplements cannot be recommended at this time for children. Options to consider for obese adolescents include increasing consumption of dietary fibre or using fibre supplements. Dietary fibre also prevents side effects of orlistat, the only medication available for treatment of obese adolescents. More research is needed to draw definitive conclusions. No single approach will successfully treat pediatric obesity, and lifestyle modification should be maintained throughout the treatment.


PRETx
Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program at the BC Children’s Hospital in Vancouver, BC. Dr Rogovik is Assistant Director and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875–2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

 

Footnotes

Competing interests

None declared

References

  1. Shields M. Measured obesity. Overweight Canadian children and adolescents. Nutrition: findings from the Canadian Community Health Survey, 1, Ottawa, ON: Statistics Canada; 2005. Available from: www.statcan.ca/english/research/82-620-MIE/2005001/pdf/cobesity.pdf. Accessed 2008 Jul 11.
  2. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176(8):S1–13.[Free Full Text]
  3. Wilson KM, Klein JD, Sesselberg TS, Yussman SM, Markow DB, Green AE, et al. Use of complementary medicine and dietary supplements among U.S. adolescents. J Adolesc Health 2006;38(4):385–94.[Medline]
  4. Bartels CL, Miller SJ. Dietary supplements marketed for weight loss. Nutr Clin Pract 2003;18(2):156–69.[Free Full Text]
  5. Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev 2005;6(2):93–111.[Medline]
  6. Favreau JT, Ryu ML, Braunstein G, Orshansky G, Park SS, Coody GL, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002;136(8):590–5.[Abstract/Free Full Text]
  7. Bryant SM, Lozada C, Wahl M. A Chinese herbal weight loss product adulterated with fenfluramine. Ann Emerg Med 2005;46(2):208.[Medline]
  8. Hsiao AL, Santucci KA, Seo-Mayer P, Mariappan MR, Hodsdon ME, Banasiak KJ, et al. Pediatric fatality following ingestion of dinitrophenol: postmortem identification of a "dietary supplement". Clin Toxicol 2005;43(4):281–5.
  9. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289(12):1537–45. Epub 2003 Mar 10.[Abstract/Free Full Text]
  10. Bent S, Padula A, Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol 2004;94(10):1359–61.[Medline]
  11. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord 2003;27(4):522–9.[Medline]
  12. Ni Mhurchu C, Dunshea-Mooij CA, Bennett D, Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst Rev 2005;(3):CD003892.
  13. Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies. J Lipid Res 2003;44(12):2234–41. Epub 2003 Aug 16.[Abstract/Free Full Text]
  14. Heymsfield SB, Aronne LJ, Blackburn GL. HCA efficiency. Diabetes Obes Metab 2004;6(6):458–9.[Medline]
  15. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004;79(4):529–36.[Abstract/Free Full Text]
  16. Slavin JL. Dietary fiber and body weight. Nutrition 2005;21(3):411–8.[Medline]
  17. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med 2005;11(6):30–4.[Medline]
  18. Moreno LA, Tresaco B, Bueno G, Fleta J, Rodriguez G, Garagorri JM, et al. Psyllium fibre and the metabolic control of obese children and adolescents. J Physiol Biochem 2003;59(3):235–42.[Medline]
  19. Dunican KC, Desilets AR, Montalbano JK. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother 2007;41(9):1445–55. Epub 2007 Jul 24.[Abstract/Free Full Text]
  20. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001;25(7):1095–9.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Résumé
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rogovik, A. L.
Right arrow Articles by Goldman, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogovik, A. L.
Right arrow Articles by Goldman, R. D.

HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH